There is no universal approach to cancer treatment, which is why we are committed to understanding the differences in patients’ clinical and non-clinical characteristics and how this can impact the therapeutic benefit of our medicines.[14]
We are pioneering a cutting-edge approach to our scientific methodologies and technologies[15], which enables us to adapt our discovery and development initiatives to drive our next wave of innovation.[4],[5]
We are pushing the boundaries of our understanding of prostate cancer and unlocking innovative ways to tackle it before it progresses. When it comes to treating cancer, it’s long been known that catching the disease in its early stages is key for a more successful outcome.[15] The premise behind the new strategy, which aims to halt or prevent cancer, is to understand why some healthy cells turn cancerous, so medications can be developed to interrupt that process – and potentially thwart the disease before it invades the body.[16]
What’s more, we have more than 30 years’ experience in oncology, and our commitment to innovation runs deeply within everyone at Johnson & Johnson Oncology.[17] We put our focus where we can make the most meaningful difference. We’re driven only to deliver the best outcomes to patients, partners, and the oncology community.